You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Tivicay pills

Build a regimen with DOLUTEGRAVIR▼ at the core

TIVICAY, the first once daily, un-boosted integrase inhibitor[1]

A visual exploration of Dolutegravir and its structure-function relationship

View

Data & Resources

Get access to electronic reprints of the key clinical data supporting Tivicay and additional resources for Healthcare Professionals

Access

 

Tivicay is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-Infected adults, adolescents and children above 6 years of age.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq is registered trademark of the GlaxoSmithKline Group of Companies